ArticleCurrent protocols2026
Mycobacterium tuberculosis and SARS-CoV-2 Co-Infection: An Efficient Cell Model to Study Lung Host-Pathogen Interactions.
Article in Current protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mycobacterium tuberculosis and SARS-CoV-2 Co-Infection: An Efficient Cell Model to Study Lung Host-Pathogen Interactions.Current protocols · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In less than a year, SARS-CoV-2 managed to displace Mycobacterium tuberculosis (Mtb) as the leading cause of death worldwide due to a single infectious agent. Both pathogens affect the respiratory tract, mainly the lungs. However, the impact that a possible Mtb + SARS-CoV-2 co-infection can have on the host response is still unknown. Herein we depict a rigorous system to evaluate the complex interaction between two simultaneous infections in vitro in a lung epithelial cell line (A549). Overall, the process includes eight steps: (1) Mtb culture, (2) cell maintenance, (3) preparation of viral stocks, (4) determination of infectious titers, (5) Mtb and SARS-CoV-2 co-infection, (6) determination of intracellular bacterial load, (7) SARS-CoV-2 viability test, and (8) optional UV-C validation assay for infectivity reduction. This comprehensive protocol will allow experimentalists to study the pathogenesis of co-infection in vitro and facilitate collaborative work in the literature. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol: In vitro coinfection model using Mtb and SARS-CoV-2 in human lung epithelial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.